Adrenocortical carcinoma: effect of hospital volume on patient outcome
- 320 Downloads
Optimal management of adrenocortical carcinoma (ACC) involves a detailed diagnostic workup, radical surgery, and appropriate adjuvant therapy. However, due to the rarity of this disease, adequate expertise is necessary to ensure optimal patient care. We evaluated if the experience of a treating center influences the outcome of ACC.
Two hundred sixty-three patients who underwent adrenalectomy for ACC were included in a multi-institutional surgical survey and divided into 2 groups: “high-volume center” (HVC) (≥10 adrenalectomies for ACC) and “low-volume center” (LVC) (<10 adrenalectomies for ACC). A comparative analysis was performed.
One hundred seventy-two patients underwent adrenalectomy at HVC and 91 at LVC. The two groups were homogeneous for age, sex, clinical presentation, and stage. The mean lesions size of ACC was higher in HVC than in LVC (104.1 ± 54.6 vs 82.8 ± 41.3 mm; P < 0.001). A significantly higher rate of lymph node dissection (P < 0.01) and of multiorgan resection (P < 0.01) was accomplished in HVC. The number of patients who underwent adjuvant therapy was significantly higher in HVC (P < 0.001). Local recurrence rate was lower in patients treated at HVC (6% vs 18.5%; P = NS). Mean time to recurrence was significantly longer in HVC than in LVC (25.2 ± 28.1 vs 10.1 ± 7.5; P < 0.01).
The expertise of dedicated centers had a positive impact on the outcome of patients with ACC, resulting in a lower recurrence rate and improved mean time to recurrence. The improved patient outcome could be related not only to the appropriateness of the surgical procedure, but also to a more adequate multidisciplinary approach.
KeywordsAdrenocortical carcinoma Patient volume Oncologic outcome Adrenal tumor
We wish to thank Antonio Ambrosi (University of Foggia), Giuseppe Cucchiara (Hospital “Fatebenefratelli”, Rome), Giorgio Giannone (Hospital “Garibaldi - Nesima”, Catania), Gianluigi Melotti (Baggiovara Hospital, Modena), Fabio Procacciante (University “La Sapienza”, Rome), Emilio Trabucchi (University of Milano, Milan), Franco Uggeri (University of Milano Bicocca, Monza) for participating in and for their contribution in updating the Italian ACC multi-institutional surgical survey.
Conflicts of interest
- 8.Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 25:891–897PubMedCrossRefGoogle Scholar
- 10.Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650–2655PubMedCrossRefGoogle Scholar
- 11.Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, Favia G, Borrelli D, Boffi L, Capussotti L, Carbone G, Casaccia M, Cavallaro A, Del Gaudio A, Dettori G, Di Giovanni V, Mazziotti A, Marrano D, Masenti E, Miccoli P, Mosca F, Mussa A, Petronio R, Piat G, Marzano L et al (1997) Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 122:1212–1218PubMedCrossRefGoogle Scholar
- 13.Fassnach M, Johanssen S, Fenske W, Weismann D, Agha A, Beusclein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Sphn M, Hahner S, Allolio B (2010) Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrin Metab 95:4925–4932CrossRefGoogle Scholar
- 16.Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H, Haaf M, Kroiss M, Jurowich C, Langer P, Oelkers W, Spahn M, Willenberg HS, Mäder U, Allolio B, Fassnacht M (2010) Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int 107(50):885–891PubMedGoogle Scholar
- 18.Villar JM, Moreno P, Ortega J, Bollo E, Ramírez CP, Muñoz N, Martínez C, Domínguez-Adame E, Sancho J, del Pino JM, Couselo JM, Carrión A, Candel M, Cáceres N, Octavio JM, Mateo F, Galán L, Ramia JM, Aguiló J, Herrera F (2010) Results of adrenal surgery. Data of a Spanish national survey. Langebecks Arch Surg 395:837–843CrossRefGoogle Scholar
- 19.Anonymous (2002) NIH state-of-the-science statement on management of the clinically unapparent adrenal mass (“incidentaloma”). NIH Consensus State Sci Statements 19(2):1–25Google Scholar
- 22.Sulivan M, Boileau M, Hodges CV (1958) Adrenal cortical carcinoma. J Urol 120:155–186Google Scholar
- 25.Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M, German Adrenocortical Carcinoma Registry Group (2010) Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 58:609–615PubMedCrossRefGoogle Scholar
- 26.Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi P, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A (2007) Adjuvant mitotane treatment in patients with adrenocortical carcinoma. N Engl J Med 356:372–380CrossRefGoogle Scholar